Charting Survivin specific T cells in cancer patients with Head and Neck Squamous Cell Carcinoma

Recruiting

Conditions: Head and Neck cancer
HNSCC
10027655

Registration Number: NL-OMON33346

Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 30

Inclusion Criteria

The patients in this study must have a histological confirmation of Head and Neck carcinoma stage 3 or higher.
Patients must be over 18 years of age. There is no maximum age.
Patients must be capable of giving informed consent.
Patients must have a life expectancy of at least 3 months.
Patients must be HLA-A2 positive.

Exclusion Criteria

Patients are excluded when pregnant.
Patients are excluded when anemic.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary; Charting the presence of tumour specific T cells will be performed<br /><br>employing tetramer staining. In house made HLA-A1 and HLA-A2 tetramers will be<br /><br>used to detect T cells directed against known antigenic peptide sequences<br /><br>derived from the tumour antigen survivin. This will document the presence of T<br /><br>cells with such specificities as a percentage of total CD8 positive T cells. It<br /><br>is expected that in about half of the patients survivin specific T cells will<br /><br>be detectable. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary; Since tetramers are available containing antigenic peptides derived<br /><br>from tumour antigens other than survivin, it is possible to chart the immune<br /><br>reactivity against these antigens simultaneously. We will do so employing<br /><br>tetramers with a fluorescent marker different form the one used for survivin.<br /><br>Tertiary; Tetramer positive T cells will be isolated from these samples when<br /><br>possible.</p><br>